The AJMC® Gastroenterology compendium is a comprehensive resource for clinical news and expert insights for diseases related to the stomach, digestive tract, colon, and more.
July 8th 2025
Although use of corticosteroid premedication prior to infliximab infusions is declining, it remains unnecessarily high despite limited benefit and the risk of serious adverse events from corticosteroids.
Managed Care Insights on the Advances in the Eosinophilic Esophagitis Treatment Landscape
1.0 Credit / Gastroenterology, Immunology, Rare Diseases
View More
Navigating the Changing Treatment Paradigm of Metabolic Dysfunction-Associated Steatohepatitis: A Guide for Managed Care Pharmacists
1.5 Credits / Endocrinology, Diabetes & Metabolism, Gastroenterology
View More
Emerging Treatment Options for Inflammatory Bowel Disease: A Focus on IL-23 Pathway Inhibition
1.5 Credits / Gastroenterology, Immunology
View More
Transforming Metabolic Dysfunction-Associated Steatohepatitis Management: Pharmacist Considerations for the Evolving Treatment Landscape
1.5 Credits / Gastroenterology
View More
Innovations in Inflammatory Bowel Disease Therapy: How IL-23 Inhibitors Are Shaping Treatment and Managed Care Approaches
1.5 Credits / Gastroenterology, Immunology
View More
Gene Variant, Season of Birth Identified as Celiac Disease Risk Factors
January 23rd 2025Children born in spring or summer with a specific gene variant may have a higher risk of celiac disease and lower levels of a key protein, according to a study, potentially helping future research on autoimmune diseases.
Read More
Study Finds Link Between COVID-19 and Elevated Risk of GI Disorders
January 14th 2025A study found that patients with COVID-19 may have a higher risk of developing new gastrointestinal (GI) disorders compared with matched controls, highlighting the need for further research on long-term GI effects post COVID-19 infection.
Read More
What Adjunct Therapies Are Most Effective for IBS, IBD?
January 13th 2025A study suggests that adjunct therapies, including the Mediterranean diet, physical activity, and cognitive behavioral therapy, may help alleviate persistent digestive symptoms and improve quality of life for patients with irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), alongside standard drug treatments.
Read More
Stable Patient Satisfaction Found After Switching From Humira or Biosimilar Adalimumab to CT-P17
January 7th 2025A real-world study in France found patient satisfaction was stable after switching from either the reference product or a low-concentration adalimumab biosimilar to the adalimumab biosimilar CT-P17, a high-concentration, citrate-free formulation.
Read More